American Heart Journal
Volume 148, Issue 1 , Pages 52-61, July 2004

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials☆

  • The ONTARGET/TRANSCEND Investigators

      Affiliations

    • Hamilton, Ontario, Canada
    • Corresponding Author InformationReprint requests: Koon K. Teo, MD, Room 3U4, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5.
    • See Appendix for Writing Group.
    • Corresponding Author InformationReprint requests: Koon K. Teo, MD, Room 3U4, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5.
    • teok@mcmaster.ca

Received 7 October 2003; accepted 26 March 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Boehringer-Ingelheim GmbH is the main sponsor and GlaxoSmithKline a cosponsor of the ONTARGET/TRANSCEND Trials.

PII: S0002-8703(04)00146-2

doi:10.1016/j.ahj.2004.03.020

American Heart Journal
Volume 148, Issue 1 , Pages 52-61, July 2004

Article Tools

* Image Usage & Resolution